Treatment of benign prostatic hyperplasia [24]

Lancet

Volumn 347, Issue 9010, 1996, Pages 1270-

  Andersen, J T ^a   Lepor, H ^a   Nitti, V W ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; FINASTERIDE; TERAZOSIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LETTER; MALE; MICTURITION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; URINE RETENTION;

EID: 15844378209     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90794-1     Document Type: Letter

References (5)

1. Vw Nitti H. Lepor Controversies old and new Lancet 346 suppl 1995 26
2. Jt Andersen P. Ekman H. Wolf Can finasteride reverse the progression of benign prostatic hyperplasia? A two-year placebo-controlled study Urology 46 1995 631 637
3. Mj Barry Wo Williford Y. Chang Benign prostatic hyperplasia health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 154 1995 1770 1774
4. Cg Roehrborn Je Osterling S. Auerbach The hytrin community assessment trial: a one-year study of terazosin versus placebo in the treatment of BPH Urology 47 1996 159 168
5. H. Lepor A Department of Veterans Affairs cooperative randomized placebo controlled clinical trial of the safety and efficacy of terazosin, finasteride monotherapy and terazosin/finasteride combination therapy in men with clinical BPH J Urol 155 1996 S87A for the VA Cooperative Studies BPH Study Group